AIM AIM ImmunoTech

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

OCALA, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”), today announced it will participate at the, taking place October 22-23, 2025 in New York, NY. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries.

As part of the conference, members of management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. To view the Company’s Maxim Growth Summit presentation slide deck, please visit the on .

For more information and a complete agenda of the Maxim Growth Summit, please visit .

About Maxim Group

Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The independent and employee-owned firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services. Maxim Group LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB) and is a member of FINRA, SIPC, and NASDAQ. To learn more about Maxim Group LLC, visit maximgrp.com.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials. Ampligen is currently being studied in collaboration with AstraZeneca in combining AIM’s drug with durvalumab for the treatment of metastatic pancreatic cancer.

For more information, please visit  and connect with the Company on , , and .



Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
EN
20/10/2025

Underlying

AIMAIM ImmunoTech

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AIM ImmunoTech

 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Announces Release of the Next CEO Corner Segment Tom Equels, CEO of AIM ImmunoTech, discusses the unmet need and driving Ampligen forward in pancreatic cancer OCALA, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced the next  segment has been published on the Company’s website. In this latest CEO Corner segment, AIM Chief Executive Officer Thomas Equels discusses the unmet need in pancreatic cancer and the Company’s lead program, Ampligen® (rintatolimod), and its ongoing evaluation in the DURIPANC Phase 1b/2 clinical t...

December 10, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Inves...

AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, December 4th at 4:00 PM ET OCALA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) announced today that of AIM will participate in the on Thursday, December 4, 2025 at 4:00 PM ET.  As part of the event, Equels will participate in a moderated “fireside” chat that will focus on AIM’s clinical and regulatory strategy for its lead drug Ampligen, with an emphasis on th...

December 1, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highli...

AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program OCALA, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”), today provided a business update and reported its financial results for the third quarter 2025. “The third quarter was marked by solid and positive clinical and operational execution. Our clinical, manufacturing and regulatory teams are heavily focused on moving Ampligen down a pathway toward eventual FDA approval as part of a c...

November 18, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial I...

AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer OCALA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today detailed a recent abstract containing data from the completed Phase 2 advanced recurrent ovarian cancer clinical study utilizing Ampligen (rintatolimod), which was presented at the on November 7, 2025, at National Harbor, MD. Platinum-sensitive patients with measurable peritoneal disease were eligible for combination therapy ...

November 10, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces Late Breaking Abstract from University of Pit...

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing Ampligen® (rintatolimod) was accepted in a late-breaking abstract at the being held November 5-9, 2025 at National Harbor, MD. Details of the poster presentation are as follows: ...

November 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch